Are You a TMBeliever? Mutations and Atezolizumab Response in Solid Tumors
- PMID: 35257152
- DOI: 10.1158/2159-8290.CD-21-1642
Are You a TMBeliever? Mutations and Atezolizumab Response in Solid Tumors
Abstract
Optimizing the utility of tumor mutational burden in solid tumors remains an unmet need and a clinical knowledge gap. Using a centrally determined cutoff of ≥16 mut/Mb, Friedman and colleagues demonstrate an ability to enrich for atezolizumab response in a pretreated pan-cancer multibasket study. See related article by Friedman et al., p. 654 (4).
©2022 American Association for Cancer Research.
Comment on
-
Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study.Cancer Discov. 2022 Mar 1;12(3):654-669. doi: 10.1158/2159-8290.CD-21-0450. Cancer Discov. 2022. PMID: 34876409 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous